Clinical Trials Browser

Interventional × Vemurafenib × 90 days × Clear all

NCT01709292 2026-04-16

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT06561360 2026-04-15

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT03155620 2026-04-14

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2 Active not recruiting

1,377 enrolled 10 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT04302025 2026-04-03

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02693535 2026-04-02

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT05068752 2026-03-30

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Phase 2 Completed

10 enrolled 15 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03178552 2026-03-09

B-FAST

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Active not recruiting

Melanoma, Skin Neoplasms

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

921 enrolled 48 charts 2 FDA

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT01659151 2026-02-20

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Phase 2 Completed

17 enrolled 11 charts

Melanoma, Neoplasm Metastasis

NCT03410875 2026-02-12

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell

NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Phase 2 Recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms